Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Collapse authors list.
van der Wouden, CH, Cambon-Thomsen, A, Cecchin, E, Cheung, KC, Davila-Fajardo, CL, Deneer, VH, Dolzan, V, Ingelman-Sundberg, M, Jonsson, S, Karlsson, MO et al (show 15 more authors) , Kriek, M, Mitropoulou, C, Patrinos, GP, Pirmohamed, M ORCID: 0000-0002-7534-7266, Samwald, M, Schaeffeler, E, Schwab, M, Steinberger, D, Stingl, J, Sunder-Plassmann, G, Toffoli, G, Turner, RM ORCID: 0000-0002-7315-679X, Van Rhenen, Mh, Swen, JJ and Guchelaar, H-J (2017) Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. CLINICAL PHARMACOLOGY & THERAPEUTICS, 101 (3). pp. 341-358.

Text UPGx review CPT.pdf - Author Accepted Manuscript Download (2MB)

Abstract

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

Item Type:	Article
Uncontrolled Keywords:	Ubiquitous Pharmacogenomics Consortium, Humans, Treatment Outcome, Prospective Studies, Genotype, Research Design, Cost-Benefit Analysis, Europe, Practice Guidelines as Topic, Electronic Health Records, Biomarkers, Precision Medicine, Pharmacogenomic Testing
Depositing User:	Symplectic Admin
Date Deposited:	09 Jan 2017 11:28
Last Modified:	19 Jan 2023 07:23
DOI:	10.1002/cpt.602
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3005030